Oral contraceptives are highly preferable as a first-line treatment for patients without contraindications, on grounds of their efficacy in preventing recurrence of pelvic pain and endometriosis lesions. However, they are associated with possible side effects such as mood changes, nausea, and elevated blood pressure levels. Progestins, on the other hand, require to be consumed periodically, unlike oral contraceptives, which require regular consumption.
By 2029, the drug category will represent a billion-dollar opportunity. Furthermore, market players are unlocking new revenue streams in gonadotropin-releasing hormone (GnRH) analogues for relevant value creation.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Europe and North America will maintain their supremacy in the global endometriosis treatment market, with the latter expected to cross US$ 1 Bn in 2020. Incumbents are pairing with healthcare providers to raise awareness in the field of endometriosis at physician and patient levels.
While these developed regional markets maintain a positive trend, stakeholders are eyeing Asia for further revenue lines. Governments in China and India are significantly increasing their healthcare budgets in order to reach the unmet sections of society.
Oral contraceptives have been the conventional drug category for treating endometriosis. Yet, they carry the drawback of first-pass liver metabolism. Market players are rolling out novel transdermal drug delivery technologies such as topical applicators to enhance efficacy and overcome the disadvantages of oral contraceptives.
Moreover, these advanced drug delivery technologies achieve steady serum hormone concentration, and thus, are expected to become commonplace in endometriosis treatment. For instance, Noven has developed CombiPatch®, a combination (two-drug) patch that can be effectively used in endometriosis treatment.
Principal Consultant
Market player continue to bank on hormonal therapy to stay ahead of their peers in the endometriosis treatment market. FMI finds that, around 9 out of 10 medical professionals prefer hormonal replacement therapy for treating endometriosis, attributable to its enhanced effectiveness with minimum risks of breast cancer.
That being said, patients undergoing the treatment are subject to post-therapy complications such as bloating, indigestion, and leg cramps. As such, they are turning to other options, including pain management.
The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The endometriosis treatment market is likely to secure a CAGR of 10.6% through 2032.
The endometriosis treatment market size is estimated to cross US$ 3.55 Billion by 2032.
The endometriosis treatment market is likely to record a value of US$ 1.30 Billion in 2022.
Europe is likely to lead the endometriosis treatment market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Drug Development Trends 4. Key Success Factors 4.1. Product Adoption / Usage Analysis 4.2. Endometriosis Epidemiology, By Key Region 4.3. Unmet Needs of Endometriosis Treatment 4.3.1. Potential Diagnostic Biomarkers for Endometriosis 4.3.1.1. Existing & Emerging Non-invasive Diagnostics Techniques 4.3.2. Disease Awareness and Educational Strategies for Medical Professionals 4.3.3. Drug Effectivity & Safety, By Drug 4.3.4. Marketed & Emerging Non-hormonal Therapies for Endometriosis 4.3.5. Disease Etiology and Pathophysiology 4.4. Research and Development Strategies 4.4.1. Reformulations and Label Expansion of Currently Marketed Drugs 4.4.2. Pipeline Assessment of GnRH Antagonists 4.4.3. Pipeline Assessment of Novel Non-hormonal Therapies 4.4.4. Key Strategies Followed By Manufacturers (Alliance, In-Licensing and Out-Licensing Strategies) 4.4.5. Strategy to Maximise Return on Investment (Drug Approvals for Secondary Indication) 4.5. Attributes/Factors Important in Clinical Trials 4.6. Clinical Trial History of Key Marketed Drugs 4.7. Attributes/Factors considered for Market Sizing of Historical Market Sizing & Opportunity Assessment of Pipeline Drugs 4.8. Pipeline Assessment/Clinical Benchmark Analysis 4.8.1. Marketed Drug/Pipeline Valuation Analysis 4.8.1.1. Therapeutic Advantages by Drug 4.8.1.2. New Drug Launches and Regulatory Approvals, 2019-2030 4.8.1.3. Opportunity Assessment in terms of Revenue, 2020-2025 4.8.1.4. Clinical Trials and Pipeline Overview 4.9. Regulatory Scenario 4.10. Reimbursement Scenario 4.11. Primary Verbatim, Key Opinion Leaders Opinion on Future Opportunities 5. Global Market Demand (Size in US$ Mn) Analysis 2014-2018 and Opportunity Assessment, 2019-2030 5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018 5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2030 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Market Background 6.1. Macro-Economic Factors 6.1.1. Global GDP Growth Outlook 6.1.2. Global Healthcare Outlook 6.1.3. Per Capita Healthcare Expenditure Outlook 6.2. Opportunity Assessment Factors - Relevance & Impact 6.2.1. Prevalence of Endometriosis 6.2.2. Growing Healthcare Expenditure 6.2.3. Increasing Number of Clinical Trials 6.2.4. Regulatory Policy Changes 6.3. Market Dynamics 6.3.1. Drivers 6.3.2. Restraints 6.3.3. Opportunity Analysis 7. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Drug 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) Analysis By Drug, 2014-2018 7.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Drug, 2019-2030 7.3.1. Oral Contraceptives 7.3.2. Progestins 7.3.3. NSAIDs 7.3.4. GnRH Analogues 7.3.5. LNR-IUDs 7.3.6. Others 7.4. Market Attractiveness Analysis By Drug 8. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Treatment Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2014-2018 8.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Treatment Type, 2019-2030 8.3.1. Hormonal Therapy 8.3.2. Pain management 8.4. Market Attractiveness Analysis By Treatment Type 9. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2014-2018 9.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Distribution Channel, 2019-2030 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Drugstores 9.3.4. E-commerce 9.4. Market Attractiveness Analysis By Distribution Channel 10. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Region 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2014-2018 10.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Region, 2019-2030 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. East Asia 10.3.5. South Asia 10.3.6. Oceania 10.3.7. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 11.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 11.3.1. By Country 11.3.1.1. U.S. 11.3.1.2. Canada 11.3.2. By Drug 11.3.3. By Treatment Type 11.3.4. By Distribution Channel 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Drug 11.4.3. By Treatment Type 11.4.4. By Distribution Channel 11.5. Key Market Participants - Intensity Mapping 11.6. Drivers and Restraints - Impact Analysis 12. Latin America Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 12.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Mexico 12.3.1.3. Argentina 12.3.1.4. Rest of Latin America 12.3.2. By Drug 12.3.3. By Treatment Type 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Drug 12.4.3. By Treatment Type 12.4.4. By Distribution Channel 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Europe Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 13.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. Italy 13.3.1.3. France 13.3.1.4. U.K. 13.3.1.5. Spain 13.3.1.6. BENELUX 13.3.1.7. Russia 13.3.1.8. Rest of Europe 13.3.2. By Drug 13.3.3. By Treatment Type 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug 13.4.3. By Treatment Type 13.4.4. By Distribution Channel 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. South Asia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 14.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 14.3.1. By Country 14.3.1.1. India 14.3.1.2. Thailand 14.3.1.3. Indonesia 14.3.1.4. Malaysia 14.3.1.5. Rest of South Asia 14.3.2. By Drug 14.3.3. By Treatment Type 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug 14.4.3. By Treatment Type 14.4.4. By Distribution Channel 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. East Asia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 15.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug 15.3.3. By Treatment Type 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug 15.4.3. By Treatment Type 15.4.4. By Distribution Channel 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. Oceania Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 16.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Drug 16.3.3. By Treatment Type 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug 16.4.3. By Treatment Type 16.4.4. By Distribution Channel 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. Middle East and Africa Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 17.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 17.3.1. By Country 17.3.1.1. GCC Countries 17.3.1.2. Turkey 17.3.1.3. Northern Africa 17.3.1.4. South Africa 17.3.1.5. Rest of Middle East and Africa 17.3.2. By Drug 17.3.3. By Treatment Type 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug 17.4.3. By Treatment Type 17.4.4. By Distribution Channel 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Emerging Countries Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. India Market Analysis 18.2.1. Introduction 18.2.2. PEST Analysis 18.2.3. Market Value Analysis by Market Taxonomy 18.2.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy 18.2.4.1. By Drug 18.2.4.2. By Treatment Type 18.2.4.3. By Distribution Channel 18.3. China Market Analysis 18.3.1. Introduction 18.3.2. PEST Analysis 18.3.3. Market Value Analysis by Market Taxonomy 18.3.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy 18.3.4.1. Drug 18.3.4.2. By Treatment Type 18.3.4.3. By Distribution Channel 18.4. Brazil Market Analysis 18.4.1. Introduction 18.4.2. PEST Analysis 18.4.3. Market Value Analysis by Market Taxonomy 18.4.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy 18.4.4.1. By Drug 18.4.4.2. By Treatment Type 18.4.4.3. By Distribution Channel 19. U.S. Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 19.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 19.3.1. By Drug 19.3.2. By Treatment Type 19.3.3. By Distribution Channel 19.4. Market Attractiveness Analysis 20. Canada Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 20.1. Introduction 20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 20.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 20.3.1. By Drug 20.3.2. By Treatment Type 20.3.3. By Distribution Channel 20.4. Market Attractiveness Analysis 21. Mexico Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 21.1. Introduction 21.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 21.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 21.3.1. By Drug 21.3.2. By Treatment Type 21.3.3. By Distribution Channel 21.4. Market Attractiveness Analysis 22. Germany Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 22.1. Introduction 22.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 22.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 22.3.1. By Drug 22.3.2. By Treatment Type 22.3.3. By Distribution Channel 22.4. Market Attractiveness Analysis 23. U.K. Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 23.1. Introduction 23.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 23.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 23.3.1. By Drug 23.3.2. By Treatment Type 23.3.3. By Distribution Channel 23.4. Market Attractiveness Analysis 24. France Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 24.1. Introduction 24.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 24.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 24.3.1. By Drug 24.3.2. By Treatment Type 24.3.3. By Distribution Channel 24.4. Market Attractiveness Analysis 25. Italy Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 25.1. Introduction 25.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 25.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 25.3.1. By Drug 25.3.2. By Treatment Type 25.3.3. By Distribution Channel 25.4. Market Attractiveness Analysis 26. Spain Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 26.1. Introduction 26.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 26.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 26.3.1. By Drug 26.3.2. By Treatment Type 26.3.3. By Distribution Channel 26.4. Market Attractiveness Analysis 27. Russia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 27.1. Introduction 27.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 27.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 27.3.1. By Drug 27.3.2. By Treatment Type 27.3.3. By Distribution Channel 27.4. Market Attractiveness Analysis 27.5. Market Attractiveness Analysis 28. Japan Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 28.1. Introduction 28.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 28.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 28.3.1. By Drug 28.3.2. By Treatment Type 28.3.3. By Distribution Channel 28.4. Market Attractiveness Analysis 29. South Korea Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 29.1. Introduction 29.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 29.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 29.3.1. By Drug 29.3.2. By Treatment Type 29.3.3. By Distribution Channel 29.4. Market Attractiveness Analysis 30. Australia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 30.1. Introduction 30.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 30.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 30.3.1. By Drug 30.3.2. By Treatment Type 30.3.3. By Distribution Channel 30.4. Market Attractiveness Analysis 31. New Zealand Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 31.1. Introduction 31.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 31.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 31.3.1. By Drug 31.3.2. By Treatment Type 31.3.3. By Distribution Channel 31.4. Market Attractiveness Analysis 32. GCC Countries Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 32.1. Introduction 32.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 32.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 32.3.1. By Drug 32.3.2. By Treatment Type 32.3.3. By Distribution Channel 32.4. Market Attractiveness Analysis 33. South Africa Market Analysis 2014-2018 and Opportunity Assessment 2019-2030 33.1. Introduction 33.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018 33.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030 33.3.1. By Drug 33.3.2. By Treatment Type 33.3.3. By Distribution Channel 33.4. Market Attractiveness Analysis 34. Market Structure Analysis 34.1. Market Analysis by Tier of Companies 34.2. Market Share Analysis of Top Players 34.3. Company Share Analysis 34.4. Market Presence Analysis 34.4.1. By Regional footprint of Players 34.4.2. Channel Foot Print by Players 35. Competition Analysis 35.1. Competition Dashboard 35.2. Competition Benchmarking 35.3. Competition Deep Dive (Tentative List) 35.3.1. AbbVie Inc. 35.3.1.1. Overview 35.3.1.2. Service Portfolio 35.3.1.3. Profitability by Market Segments (Service/Channel/Region) 35.3.1.4. Sales Footprint 35.3.1.5. Strategy Overview 35.3.1.5.1. Marketing Strategy 35.3.1.5.2. Service Strategy 35.3.1.5.3. Channel Strategy 35.3.2. Bayer AG 35.3.2.1. Overview 35.3.2.2. Service Portfolio 35.3.2.3. Profitability by Market Segments (Service/Channel/Region) 35.3.2.4. Sales Footprint 35.3.2.5. Strategy Overview 35.3.2.5.1. Marketing Strategy 35.3.2.5.2. Service Strategy 35.3.2.5.3. Channel Strategy 35.3.3. AstraZeneca 35.3.3.1. Overview 35.3.3.2. Service Portfolio 35.3.3.3. Profitability by Market Segments (Service/Channel/Region) 35.3.3.4. Sales Footprint 35.3.3.5. Strategy Overview 35.3.3.5.1. Marketing Strategy 35.3.3.5.2. Service Strategy 35.3.3.5.3. Channel Strategy 35.3.4. Pfizer Inc. 35.3.4.1. Overview 35.3.4.2. Service Portfolio 35.3.4.3. Profitability by Market Segments (Service/Channel/Region) 35.3.4.4. Sales Footprint 35.3.4.5. Strategy Overview 35.3.4.5.1. Marketing Strategy 35.3.4.5.2. Service Strategy 35.3.4.5.3. Channel Strategy 35.3.5. Teva Pharmaceutical Industries Ltd. 35.3.5.1. Overview 35.3.5.2. Service Portfolio 35.3.5.3. Profitability by Market Segments (Service/Channel/Region) 35.3.5.4. Sales Footprint 35.3.5.5. Strategy Overview 35.3.5.5.1. Marketing Strategy 35.3.5.5.2. Service Strategy 35.3.5.5.3. Channel Strategy 35.3.6. Ipsen Pharma 35.3.6.1. Overview 35.3.6.2. Service Portfolio 35.3.6.3. Profitability by Market Segments (Service/Channel/Region) 35.3.6.4. Sales Footprint 35.3.6.5. Strategy Overview 35.3.6.5.1. Marketing Strategy 35.3.6.5.2. Service Strategy 35.3.6.5.3. Channel Strategy 35.3.7. Myovant Sciences 35.3.7.1. Overview 35.3.7.2. Service Portfolio 35.3.7.3. Profitability by Market Segments (Service/Channel/Region) 35.3.7.4. Sales Footprint 35.3.7.5. Strategy Overview 35.3.7.5.1. Marketing Strategy 35.3.7.5.2. Service Strategy 35.3.7.5.3. Channel Strategy 35.3.8. Endoceutics, Inc. 35.3.8.1. Overview 35.3.8.2. Service Portfolio 35.3.8.3. Profitability by Market Segments (Service/Channel/Region) 35.3.8.4. Sales Footprint 35.3.8.5. Strategy Overview 35.3.8.5.1. Marketing Strategy 35.3.8.5.2. Service Strategy 35.3.8.5.3. Channel Strategy 35.3.9. Debiopharm Group 35.3.9.1. Overview 35.3.9.2. Service Portfolio 35.3.9.3. Profitability by Market Segments (Service/Channel/Region) 35.3.9.4. Sales Footprint 35.3.9.5. Strategy Overview 35.3.9.5.1. Marketing Strategy 35.3.9.5.2. Service Strategy 35.3.9.5.3. Channel Strategy 35.3.10. Mayne Pharma Group Limited 35.3.10.1. Overview 35.3.10.2. Service Portfolio 35.3.10.3. Profitability by Market Segments (Service/Channel/Region) 35.3.10.4. Sales Footprint 35.3.10.5. Strategy Overview 35.3.10.5.1. Marketing Strategy 35.3.10.5.2. Service Strategy 35.3.10.5.3. Channel Strategy 35.3.11. Noven Pharmaceuticals, Inc. 35.3.11.1. Overview 35.3.11.2. Service Portfolio 35.3.11.3. Profitability by Market Segments (Service/Channel/Region) 35.3.11.4. Sales Footprint 35.3.11.5. Strategy Overview 35.3.11.5.1. Marketing Strategy 35.3.11.5.2. Service Strategy 35.3.11.5.3. Channel Strategy 35.3.12. Sun Pharmaceutical Industries Limited 35.3.12.1. Overview 35.3.12.2. Service Portfolio 35.3.12.3. Profitability by Market Segments (Service/Channel/Region) 35.3.12.4. Sales Footprint 35.3.12.5. Strategy Overview 35.3.12.5.1. Marketing Strategy 35.3.12.5.2. Service Strategy 35.3.12.5.3. Channel Strategy 35.3.13. Amneal Pharmaceuticals, Inc. Market_Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2030 35.3.13.1. Overview 35.3.13.2. Service Portfolio 35.3.13.3. Profitability by Market Segments (Service/Channel/Region) 35.3.13.4. Sales Footprint 35.3.13.5. Strategy Overview 35.3.13.5.1. Marketing Strategy 35.3.13.5.2. Service Strategy 35.3.13.5.3. Channel Strategy 35.3.14. Mylan N.V. 35.3.14.1. Overview 35.3.14.2. Service Portfolio 35.3.14.3. Profitability by Market Segments (Service/Channel/Region) 35.3.14.4. Sales Footprint 35.3.14.5. Strategy Overview 35.3.14.5.1. Marketing Strategy 35.3.14.5.2. Service Strategy 35.3.14.5.3. Channel Strategy 35.3.15. Aurobindo Pharma 35.3.15.1. Overview 35.3.15.2. Service Portfolio 35.3.15.3. Profitability by Market Segments (Service/Channel/Region) 35.3.15.4. Sales Footprint 35.3.15.5. Strategy Overview 35.3.15.5.1. Marketing Strategy 35.3.15.5.2. Service Strategy 35.3.15.5.3. Channel Strategy 36. Assumptions and Acronyms Used 37. Research Methodology
Explore Healthcare Insights
View Reports
Endometriosis Treatment Market
